Loading…
Rossari Biotech (ROSSARI)₹424.95+0.09%Specialty Chemicals
In the Sep 2026 quarter (consolidated), Rossari Biotech reported sales of ₹696 Cr, up 19.0% from Sep 2025, and net profit of ₹39.03 Cr, up 5.3% year on year. For the year to Mar 2026, sales were ₹2,390 Cr and net profit ₹149 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 463 | 472 | 489 | 496 | 512 | 578 | 542 | 585 | 581 | 683 | 695 | 696 |
| Expenses | 399 | 408 | 423 | 431 | 446 | 508 | 475 | 512 | 512 | 606 | 615 | 609 |
| Operating Profit | 64.09 | 64.10 | 65.09 | 66.11 | 65.15 | 69.12 | 68.08 | 72.13 | 69.15 | 77.08 | 81.10 | 87.06 |
| OPM % | 13.9% | 12.9% | 12.9% | 13.0% | 13.0% | 11.9% | 12.0% | 11.9% | 11.9% | 10.9% | 11.9% | 11.9% |
| Other Income | 4.01 | 1.01 | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 1.01 | 20.04 | 4.01 | 1.01 |
| Interest | 3.99 | 2.99 | 3.99 | 3.99 | 4.98 | 5.98 | 5.98 | 5.98 | 7.97 | 8.97 | 10.97 | 8.98 |
| Depreciation | 14.94 | 15.94 | 14.94 | 14.93 | 17.92 | 17.92 | 17.93 | 17.93 | 19.92 | 23.92 | 25.89 | 29.88 |
| Profit before tax | 47.97 | 45.98 | 46.98 | 47.95 | 41.96 | 47.99 | 45.96 | 50.01 | 42.97 | 63.99 | 47.98 | 48.93 |
| Tax % | 28.0% | 25.0% | 26.0% | 27.0% | 24.9% | 28.0% | 27.0% | 26.0% | 23.0% | 28.0% | 26.0% | 21.0% |
| Net Profit | 34.03 | 34.03 | 35.01 | 35.02 | 32.01 | 34.04 | 34.05 | 37.05 | 33.06 | 46.04 | 35.02 | 39.03 |
| EPS (Rs) | 6.22 | 6.17 | 6.31 | 6.38 | 5.72 | 6.20 | 6.06 | 6.65 | 5.91 | 8.28 | 6.33 | 7.01 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 514 | 598 | 706 | 1,480 | 1,652 | 1,827 | 2,073 | 2,390 | 2,655 |
| Expenses | 437 | 494 | 584 | 1,294 | 1,428 | 1,577 | 1,810 | 2,103 | 2,341 |
| Operating Profit | 78.08 | 105 | 124 | 184 | 224 | 250 | 265 | 286 | 314 |
| OPM % | 14.9% | 16.9% | 16.9% | 11.9% | 12.9% | 13.9% | 12.9% | 11.9% | 11.8% |
| Other Income | 1.01 | 4.01 | 9.02 | 13.03 | 6.01 | 8.01 | 5.01 | 24.04 | 26.07 |
| Interest | 2.99 | 3.99 | 2.99 | 12.95 | 21.94 | 18.95 | 17.95 | 28.91 | 36.89 |
| Depreciation | 11.96 | 16.93 | 22.90 | 47.80 | 62.73 | 59.79 | 66.71 | 78.72 | 99.61 |
| Profit before tax | 62.99 | 87.95 | 107 | 136 | 144 | 178 | 185 | 203 | 204 |
| Tax % | 28.0% | 26.0% | 25.0% | 28.0% | 26.0% | 26.0% | 26.0% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 13.97 | — |
| Net Profit | 46.06 | 65.06 | 80.06 | 98.16 | 107 | 131 | 136 | 149 | 153 |
| EPS (Rs) | 9.42 | 12.84 | 15.41 | 17.69 | 19.40 | 23.62 | 24.57 | 26.88 | 27.53 |
| Dividend payout % | 0.0% | 4.0% | 3.0% | 3.0% | 3.0% | 2.0% | 2.0% | 2.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.99 | 9.96 | 9.96 | 10.95 | 10.95 | 10.96 | 10.96 | 10.96 |
| Reserves | 119 | 277 | 397 | 794 | 902 | 1,036 | 1,173 | 1,321 |
| Borrowings | 7.98 | 66.86 | 0.00 | 7.98 | 73.77 | 119 | 218 | 435 |
| Other Liabilities | 117 | 117 | 151 | 440 | 373 | 399 | 480 | 503 |
| Total Liabilities | 249 | 470 | 560 | 1,252 | 1,360 | 1,563 | 1,882 | 2,270 |
| Fixed Assets | 73.81 | 93.64 | 181 | 605 | 583 | 576 | 596 | 782 |
| CWIP | 3.01 | 22.01 | 0.00 | 1.01 | 16.01 | 47.01 | 140 | 173 |
| Investments | 0.00 | 17.98 | 0.00 | 35.96 | 50.99 | 62.99 | 83.99 | 61.95 |
| Other Assets | 173 | 337 | 378 | 610 | 710 | 878 | 1,062 | 1,252 |
| Inventories | 54.99 | 58.01 | 95.01 | 190 | 188 | 282 | 355 | 405 |
| Trade receivables | 85.80 | 93.80 | 144 | 304 | 353 | 424 | 473 | 556 |
| Cash & equivalents | 5.98 | 127 | 87.74 | 51.90 | 124 | 29.90 | 56.89 | 91.76 |
| Total Assets | 249 | 470 | 560 | 1,252 | 1,360 | 1,563 | 1,882 | 2,270 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 71.08 | 57.11 | 48.08 | 29.03 | 152 | 43.07 | 137 | 65.11 |
| Cash from investing activity | −37.05 | −190 | −37.08 | −300 | −181 | −103 | −183 | −220 |
| Cash from financing activity | −29.07 | 157 | −25.06 | 293 | 61.13 | 16.02 | 65.13 | 186 |
| Net cash flow | 5.01 | 23.08 | −14.04 | 22.08 | 32.08 | −44.15 | 19.06 | 31.08 |
| Capex | 44.14 | 76.29 | 58.20 | 38.13 | 33.12 | 131 | 159 | 266 |
| Free cash flow | 27.11 | −19.07 | −8.03 | −7.03 | 120 | −83.32 | −21.08 | −176 |
| CFO / OP % | 117.9% | 73.9% | 63.9% | 42.9% | 88.9% | 39.0% | 73.9% | 46.9% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 61 | 57 | 74 | 75 | 78 | 85 | 83 | 85 |
| Inventory days | 59 | 57 | 75 | 63 | 59 | 80 | 90 | 88 |
| Days payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 | 71 |
| Cash conversion cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 | 103 |
| Working capital days | 23 | 22 | 60 | 62 | 49 | 70 | 69 | 49 |
| ROCE % | — | 37.9% | 29.0% | 24.0% | 18.0% | 18.0% | 15.9% | 13.0% |
For the Sep 2026 quarter, Rossari Biotech reported sales of ₹696 Cr, up 19.0% year on year and net profit of ₹39.03 Cr, up 5.3% year on year. The operating margin was 11.9%.
Rossari Biotech's sales for the year to Mar 2026 were ₹2,390 Cr; over the last twelve months they were ₹2,655 Cr.
Net profit for the year to Mar 2026 was ₹149 Cr, and ₹153 Cr over the last twelve months. Earnings per share over the same trailing period were ₹27.53.
Rossari Biotech reported borrowings of ₹435 Cr at Mar 2026, against cash and equivalents of ₹91.76 Cr.
Cash from operations was ₹65.11 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹176 Cr.